A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Bristol-Myers Squibb
Taiho Oncology, Inc.
Seagen Inc.
Verastem, Inc.
Eli Lilly and Company
NeoImmuneTech
Takeda
Eli Lilly and Company
VM Oncology, LLC
Merck Sharp & Dohme LLC
Mirati Therapeutics Inc.
Eli Lilly and Company
Bicara Therapeutics
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc.
TME Pharma AG
DEKA Biosciences
OncoC4, Inc.
Redx Pharma Ltd
Intensity Therapeutics, Inc.
Merck Sharp & Dohme LLC
Carisma Therapeutics Inc
Eli Lilly and Company
Astellas Pharma Inc
NGM Biopharmaceuticals, Inc
ENB Therapeutics, Inc
ADC Therapeutics S.A.
Coherus Oncology, Inc.
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Ikena Oncology
Wellmarker Bio
Corvus Pharmaceuticals, Inc.
Fate Therapeutics
Kineta Inc.
Fate Therapeutics
Xencor, Inc.
AmMax Bio, Inc.
Incyte Corporation
GlaxoSmithKline
TME Pharma AG
Acerta Pharma BV